TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07516561: Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

Sponsor: Apsen Farmaceutica S.A. · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 336 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT07516561 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07516561 Rescue Dossier →